Effectiveness of radiotherapy for patients with indolent non-Hodgkin's lymphoma

被引：0
作者：
Hadi, I. [1 ]
Schummer, A. [1 ]
Eze, C. [1 ]
Dreyling, M. [2 ]
Belka, C. [1 ]
Li, M. [1 ]
机构：
[1] Univ Hosp LMU, Dept Radiat Oncol, Munich, Germany
[2] Univ Hosp LMU, Dept Oncol, Munich, Germany
来源：
RADIOTHERAPY AND ONCOLOGY | 2020年 / 152卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO-0913
引用
收藏
页码：S487 / S488
页数：2
相关论文
共 50 条
  • [31] Primary lymphoma of the conjunctiva - a rare manifestation of indolent non-Hodgkin's lymphoma
    Reiser, M
    Josting, A
    Diehl, V
    Engert, A
    ANNALS OF HEMATOLOGY, 2001, 80 (05) : 311 - 313
  • [32] ECONOMIC EVALUATION OF BENDAMUSTINE IN PATIENTS WITH RELAPSED INDOLENT NON-HODGKIN'S LYMPHOMA IN MEXICO
    Salazar, A.
    Aguirre, A.
    Herrera, M.
    VALUE IN HEALTH, 2017, 20 (05) : A215 - A215
  • [33] Uncertainty and coping in patients with newly diagnosed indolent non-Hodgkin's lymphoma (iNHL)
    Newcomb, Richard
    Johnson, Patrick Connor
    Yang, Daniel
    Amonoo, Hermioni L.
    Dhawale, Tejaswini More
    Chen, Yi-Bin Albert
    El-Jawahri, Areej
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [34] Chromosome aberrations in patients treated by radiotherapy for non-Hodgkin's lymphoma
    Mahe, M. A.
    Andre, M. J.
    Moyon, E.
    Le Mevel, A.
    Journal de Chimie Physique et de Physico-Chimie Biologique/International Journal of Physical Chemistry,Chemical Physics and Biophysics, 95 (04):
  • [35] Introduction: Treatment of patients with rituximab-refractory indolent non-hodgkin's lymphoma
    Gregory, Stephanie A.
    SEMINARS IN HEMATOLOGY, 2007, 44 (03) : S1 - S1
  • [36] Population pharmacokinetics of bendamustine and metabolites in patients with indolent non-hodgkin's lymphoma (NHL).
    Owen, J. S.
    Melhem, M.
    D'Andrea, D.
    Darwish, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S54 - S55
  • [37] Chromosome aberrations in patients treated by radiotherapy for non-Hodgkin's lymphoma
    Mahe, MA
    Andre, MJ
    Moyon, E
    Le Mevel, A
    Soubeyran, P
    Hamidou, M
    Milpied, N
    Bourdin, S
    Cuilliere, JC
    Chatal, JF
    JOURNAL DE CHIMIE PHYSIQUE ET DE PHYSICO-CHIMIE BIOLOGIQUE, 1998, 95 (04) : 832 - 835
  • [38] Comparison of out-of-pocket costs for patients (pts) with Hodgkin's disease (HD), indolent non-Hodgkin's lymphoma (INHL) and aggressive non-Hodgkin's lymphoma (ANHL).
    McCaffrey, K
    Fisher, M
    Kutikova, L
    Bowman, L
    Evens, A
    Gordon, L
    Auto, H
    Bennett, C
    BLOOD, 2005, 106 (11) : 631A - 631A
  • [39] Antibody and immunomodulatory agents in treatment of indolent non-Hodgkin's lymphoma
    Friedberg J.W.
    Freedman A.S.
    Current Treatment Options in Oncology, 2006, 7 (4) : 276 - 284
  • [40] Secondary malignancies after therapy of indolent non-Hodgkin's lymphoma
    Friedberg, Jonathan W.
    HAEMATOLOGICA, 2008, 93 (03) : 336 - 338
12345